[Chemotherapy of brain neoplasms in children].
D000367:Age Factors; D001254:Astrocytoma / Q000188:drug therapy; D001812:Blood-Brain Barrier; D001932:Brain Neoplasms / Q000188:drug therapy*; D002330:Carmustine / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004806:Ependymoma / Q000188:drug therapy; D005909:Glioblastoma / Q000188:drug therapy; D005910:Glioma / Q000188:drug therapy; D006801:Humans; D008527:Medulloblastoma / Q000188:drug therapy; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use; D011379:Prognosis; D011879:Radiotherapy Dosage; D013997:Time Factors; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D009607:Nitrosourea Compounds; D014750:Vincristine; D003520:Cyclophosphamide; D002330:Carmustine; D008727:Methotrexate
Chemotherapie kindlicher Hirntumoren